Replies to post #347615 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Disregard. It was 30 million from aspire

[Longpicker]

Looked to me like Kips Bay Select LP is a new entity formed just to declare the 5%+ block of shares, and stay legit

[wsbc]

This was the most recent one that seems to be the cause of some confusion around the board: https://www.sec.gov/Archives/edgar/data/1355250/000147793220007184/ipix_ex101.htm

The confusion seems to stem from 'Kips Bay' causing a 13G filing: https://www.sec.gov/Archives/edgar/data/0001845716/000121390021008496/ea135337-sc13gkipsbay_inn.htm

This is practically identical to the series of MFO filings related to Leviston Resources, which I believe you to be familiar with.

Which supersedes this updated Aspire agreement: https://www.sec.gov/Archives/edgar/data/1355250/000147793220004521/ipix_ex101.htm

To which some posters are opining Kips Bay being of unrelated business, which I'm questioning as Leviston was compelled into a 13G filing following their conversions of warrants/preferreds to common once they held >5% the 13G went into effect (several times).

My feeling is this is what transpired with Kips Bay, (as-yet unnamed by IPIX) as the most recent filer benefiting IPIX +$3M (+$2M)
(Original filing 9 Dec 2020) : https://www.sec.gov/Archives/edgar/data/1355250/000147793220007184/ipix_8k.htm

Initial Terms: Item 1.01 Entry into a Material Definitive Agreement.

On December 9, 2020, Innovation Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an investor for the sale of an aggregate of 5,089 shares of the Company’s newly-created Series B-2 5% convertible preferred stock (the “preferred stock”), for aggregate gross proceeds of approximately $5.0 million. Under the Securities Purchase Agreement, the Company will also issue to the investor warrants to purchase up to an additional 10,178 shares of preferred stock. An initial closing relating to the sale of 3,053 shares of preferred stock and accompanying warrants occurred on December 9, 2020, and a second closing relating to the sale of 2,036 shares of preferred stock and accompanying warrants is expected to occur sixty trading days following the date of the first closing, subject to the trading price for the Company’s common stock being greater than $0.07 per share and the value of the daily trading volume for the Company’s common stock being greater than $50,000, in each case for each of the ten trading days prior to the second closing date, and subject to satisfaction of customary closing conditions as set forth in the Securities Purchase Agreement.

(this is what folks here are arguing is NOT Kips Bay...)

...and my question is: If it's not Kips Bay, then there's a whole TON of unaccounted-for shares blowing in the wind from this deal with an as-of-yet undisclosed additional 'financing' party, in addition to the mystery of 'Kips Bay' suddenly materializing from the ether holding 20M shares.

I’m confused. I am long and read all filings. Where did I miss a new stock offering? There was the damn MFO that diluted the crap out of us, where I saw the first filing from Miller after years of the MFO agreement. I recently read the new aspire agreement. .10 limit and 25 million?

What are we talking about kips bay? Is there another stock agreement that I have missed?

[Justfactsmam]

rejoice...dont complain

raising capital (vs debt financing) = path to trials and success


ps NICE FIND ...GEORGE

Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture

https://www.mdpi.com/1999-4915/13/2/271 link shows number of times Peer Review Article was accessed as of Feb 9th and recited in other publications.

The abstract has been viewed over 2500 times and full artilce 500 times...Brilacidin getting known better in the scientific community.

________________________________________________________________________

Open AccessArticle
Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture
by Allison Bakovic 1,Kenneth Risner 1OrcID,Nishank Bhalla 1,Farhang Alem 1OrcID,Theresa L. Chang 2,Warren K. Weston 3,Jane A. Harness 3 andAarthi Narayanan 1,*
1
National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA 20110, USA
2
Public Health Research Institute, Rutgers, New Jersey Medical School, the State University of New Jersey, Newark, NJ 07103, USA
3
Innovation Pharmaceuticals Inc., Wakefield, MA 01880, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Deborah H. Fuller
Viruses 2021, 13(2), 271; https://doi.org/10.3390/v13020271
Received: 12 January 2021 / Revised: 28 January 2021 / Accepted: 5 February 2021 / Published: 9 February 2021
(This article belongs to the Section SARS-CoV-2 and COVID-19)
Download PDF Browse Figure Citation Export
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the newly emergent causative agent of coronavirus disease-19 (COVID-19), has resulted in more than two million deaths worldwide since it was first detected in 2019. There is a critical global need for therapeutic intervention strategies that can be deployed to safely treat COVID-19 disease and reduce associated morbidity and mortality. Increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs), also referred to as Host Defense Proteins/Peptides (HDPs), can inhibit SARS-CoV-2, paving the way for the potential clinical use of these molecules as therapeutic options. In this manuscript, we describe the potent antiviral activity exerted by brilacidin—a de novo designed synthetic small molecule that captures the biological properties of HDPs—on SARS-CoV-2 in a human lung cell line (Calu-3) and a monkey cell line (Vero). These data suggest that SARS-CoV-2 inhibition in these cell culture models is likely to be a result of the impact of brilacidin on viral entry and its disruption of viral integrity. Brilacidin demonstrated synergistic antiviral activity when combined with remdesivir. Collectively, our data demonstrate that brilacidin exerts potent inhibition of SARS-CoV-2 against different strains of the virus in cell culture.
Keywords: brilacidin; coronavirus; antiviral; defensin; peptidomimetic; entry inhibition